Testosterone Lawyers at Bernstein Liebhard LLP Comment on Issuance of New Deposition Protocol Governing Federal Testosterone Lawsuits

Share Article

The Firm is actively filing testosterone treatment lawsuits in federal court on behalf of men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism and other cardiovascular problems due to their use of low testosterone therapy.

Free Case Review
Our Firm is representing numerous testosterone plaintiffs who have filed claims in federal court, and we are pleased to see that discovery is progressing in this matter.

The federal court overseeing hundreds of federally-filed testosterone lawsuits (http://www.testosteronelawsuithub.com/) has established a new protocol governing the depositions of generic fact witnesses in the multidistrict litigation. According to an Order issued in the U.S. District Court, Northern District of Illinois on March 9th, plaintiffs are entitled to take a specific number of depositions for each defendant, which includes the depositions of individual fact witnesses, as well as depositions of corporate representatives. If plaintiffs wish to conduct additional depositions, the Order stipulates that they meet and confer with counsel to determine if an agreement can be reached on the number of additional depositions. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)

“Our Firm is representing numerous testosterone plaintiffs who have filed claims in federal court, and we are pleased to see that discovery is progressing in this matter. Depositions are a key part of the discovery process, and allow for the preservation of testimony that may be relevant to plaintiffs’ cases,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently representing a number of clients who have testosterone lawsuits pending in the federal proceeding, and continues to offer free case reviews to men who may have been harmed by low testosterone treatments.

Testosterone Litigation
According to court documents, more than 1,000 testosterone treatment lawsuits are currently pending in the federal litigation underway in the Northern District of Illinois. The proceeding was established in June 2014, just months after the U.S. Food & Drug Administration (FDA) disclosed on January 31, 2014 that it was investigating the cardiovascular side effects potentially associated with testosterone replacement therapy. The FDA has since ordered the manufacturers of low testosterone therapies to modify the drugs’ labels in order to warn patients that this class of medications may increase their risk for heart attacks and strokes. The labels must also be updated to clarify their approved uses, which do not include the treatment of low testosterone levels associated with aging.

Court records indicate that all of the testosterone treatment lawsuits currently pending in federal court similarly allege that the pharmaceutical companies engaged in the marketing of these medications concealed their association with serious cardiovascular problems. Plaintiffs further claim sales of testosterone replacement products were driven by aggressive direct-to-consumer advertising that positioned the medications as a treatment for symptoms associated with age-related drops in testosterone, when in fact they have only been approved to treat low testosterone associated with certain medical conditions, including disorders of the testicles, pituitary gland, or brain.

Men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism or other serious cardiovascular events due to their use of low testosterone therapy may be eligible for compensation for medical bills, lost wages and other injury-related damages. To learn more about filing a testosterone treatment lawsuit, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.

*fda.gov/Drugs/DrugSafety/ucm383904.htm, FDA, January 31, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website